

**PRODUCT MONOGRAPH**

**Pr**  
**AURO-CEFIXIME**

**Cefixime Tablets**

**400 mg**

**Manufacturer's Standard**

**Antibiotic**

**Auro Pharma Inc.**

3700 Steeles Avenue West, Suite # 402  
Woodbridge, Ontario, L4L 8K8  
CANADA

Submission Control No: 165308

Date of Preparation:  
October 17, 2014

## PRODUCT MONOGRAPH

### <sup>Pr</sup> AURO-CEFIXIME

Cefixime Tablets

400 mg

Manufacturer's Standard

## THERAPEUTIC CLASSIFICATION

Antibiotic

## ACTION AND CLINICAL PHARMACOLOGY

Cefixime exerts its bactericidal effect by attaching to penicillin-binding proteins (PBP) and inhibiting peptidoglycan synthesis, thus causing damage to the bacterial cell wall.

Following oral dosing, cefixime attains peak serum levels in approximately 4 hours. The half-life is about 3 to 4 hours and is not dose dependent. Cefixime is excreted by renal and biliary mechanisms. About 50% of the absorbed dose is excreted unchanged in the urine within 24 hours. There is no evidence of metabolism of cefixime in vivo.

## INDICATIONS AND USAGE

AURO-CEFIXIME (cefixime) is indicated in the treatment of the following infections caused by susceptible strains of the designated microorganisms:

### **Upper Respiratory Tract:**

Pharyngitis and tonsillitis caused by *S. pyogenes*.

### **Middle Ear:**

Otitis media caused by *S. pneumoniae*, *H. influenzae* (beta-lactamase positive and negative strains), *M. catarrhalis* (former *B. catarrhalis*) (beta-lactamase positive and negative strains) and *S. pyogenes*.

### **Paranasal sinuses:**

Sinusitis caused by *S. pneumoniae*, *H. influenzae* (beta-lactamase positive and negative strains), and *M. catarrhalis* (former *B. catarrhalis*) (beta-lactamase positive and negative strains).

### **Lower Respiratory Tract:**

Acute bronchitis caused by *S. pneumoniae*, *M. catarrhalis* (former *B. catarrhalis*) (beta-lactamase positive and negative strains) and *H. influenzae* (beta-lactamase positive and negative strains).

**Urinary Tract:**

Acute uncomplicated cystitis and urethritis caused by *E. coli*, *P. mirabilis*, and *Klebsiella* species.

**Uncomplicated Gonorrhea:**

Uncomplicated gonorrhea (cervical/urethral and rectal) caused by *Neisseria gonorrhoeae*, including penicillinase (beta-lactamase-positive) and nonpenicillinase (beta-lactamase-negative) producing strains.

Appropriate cultures should be taken for susceptibility testing before initiating treatment with AURO-CEFIXIME. If warranted, therapy may be instituted before susceptibility results are known; however, once these are obtained, therapy may need to be adjusted.

### CONTRAINDICATIONS

AURO-CEFIXIME (cefixime) is contraindicated in patients with known allergies to the cephalosporin or penicillin antibiotics or to any ingredients in the formulation or component of the container.

### WARNINGS

**Hypersensitivity:**

**IN PENICILLIN-SENSITIVE PATIENTS, AURO-CEFIXIME (CEFIXIME) SHOULD BE ADMINISTERED CAUTIOUSLY. PATIENTS MAY BE SENSITIVE TO PENICILLINS AND NOT TO CEPHALOSPORINS SUCH AS AURO-CEFIXIME OR BE SENSITIVE TO BOTH. MEDICAL LITERATURE INDICATES THAT PATIENTS SENSITIVE TO CEPHALOSPORINS ARE VERY LIKELY TO BE PENICILLIN SENSITIVE.**

Antibiotics, including AURO-CEFIXIME tablets, should be administered cautiously to any patient who has demonstrated some form of allergy, particularly to drugs.

**Severe Cutaneous Adverse Reactions:**

Severe cutaneous adverse reactions such as toxic epidermal necrolysis, Stevens-Johnson syndrome and drug rash with eosinophilia and systemic symptoms (DRESS) have been reported in some patients on cefixime tablets. When severe cutaneous adverse reactions occur, AURO-CEFIXIME tablets should be discontinued and appropriate therapy and/or measures should be taken.

***Clostridium Difficile*-Associated Disease:**

*Clostridium difficile*-associated disease (CDAD) has been reported with use of many antibacterial agents, including cefixime tablets. CDAD may range in severity from mild diarrhea

to fatal colitis. It is important to consider this diagnosis in patients who present with diarrhea, or symptoms of colitis, pseudomembranous colitis, toxic megacolon, or perforation of colon subsequent to the administration of any antibacterial agent. CDAD has been reported to occur over 2 months after the administration of antibacterial agents.

Treatment with antibacterial agents may alter the normal flora of the colon and may permit overgrowth of *Clostridium difficile*. *C. difficile* produces toxins A and B, which contribute to the development of CDAD. CDAD may cause significant morbidity and mortality. CDAD can be refractory to antimicrobial therapy.

If the diagnosis of CDAD is suspected or confirmed, appropriate therapeutic measures should be initiated. Mild cases of CDAD usually respond to discontinuation of antibacterial agents not directed against *Clostridium difficile*. In moderate to severe cases, consideration should be given to management with fluids and electrolytes, protein supplementation, and treatment with an antibacterial agent clinically effective against *Clostridium difficile*. Surgical evaluation should be instituted as clinically indicated, as surgical intervention may be required in certain severe cases.

### **Hemolytic Anemia:**

**AURO-CEFEXIME SHOULD NOT BE USED IN PATIENTS WITH A HISTORY OF CEPHALOSPORIN-ASSOCIATED HEMOLYTIC ANEMIA SINCE THE RECURRENCE OF HEMOLYSIS IS MUCH MORE SEVERE.**

An immune mediated hemolytic anemia has been observed in patients receiving cephalosporin class antibacterials, including cefixime tablets. Severe cases of hemolytic anemia, including fatalities, have been reported with cephalosporins in both adults and children. If a patient develops anemia anytime during, or within 2-3 weeks subsequent to the administration of AURO-CEFEXIME tablets, the diagnosis of a cephalosporin-associated anemia should be considered and the drug discontinued until the etiology is determined.

Patients may benefit from periodic monitoring for signs and symptoms of hemolytic anemia, including measurement of hematological parameters or drug-induced antibody testing, where appropriate (see ADVERSE REACTIONS).

### **Acute Renal Failure:**

As with other cephalosporins, AURO-CEFEXIME tablets may cause acute renal failure including tubulointerstitial nephritis. When acute renal failure occurs, AURO-CEFEXIME tablets should be discontinued and appropriate therapy and/or measures should be taken.

## **PRECAUTIONS**

### **General:**

If an allergic reaction to AURO-CEFEXIME tablets (cefixime) occurs, the drug should be

discontinued, and, if necessary, the patient should be treated with appropriate agents, e.g., pressor amines, antihistamines, or corticosteroids.

The possibility of the emergence of resistant organisms, which might result in overgrowth, should be kept in mind, particularly during prolonged treatment. In such use, careful observation of the patient is essential. If superinfection occurs during therapy, appropriate measures should be taken.

Broad-spectrum antibiotics such as AURO-CEFIXIME tablets should be prescribed with caution in individuals with a history of gastrointestinal disease.

Once daily dosing only must be used for urinary tract infections, since twice daily dosing was shown to be not as effective in clinical studies.

Do not use AURO-CEFIXIME tablets to treat *Staphylococcus aureus* as this strain of staphylococcus is resistant to cefixime.

### **Renal Impairment:**

AURO-CEFIXIME tablets should be used with particular care in the presence of severely impaired renal function. Dose modification is recommended for patients with moderate or severe renal impairment (i.e., creatinine clearance of < 40 mL/min) (see PHARMACOLOGY and DOSAGE AND ADMINISTRATION).

### **Drug/Drug Interactions:**

AURO-CEFIXIME tablets should be administered with caution to patients receiving coumarin-type anticoagulants such as warfarin potassium. Since AURO-CEFIXIME tablets may enhance effects of the anticoagulants, prolonged prothrombin time with or without bleeding may occur (see ADVERSE REACTIONS and PHARMACOLOGY).

### **Drug/Laboratory Interactions:**

A false-positive reaction for ketones in the urine may occur with tests using nitroprusside but not with those using nitroferricyanide.

The administration of beta-lactams may result in a false-positive reaction for glucose in the urine using Clinitest<sup>\*</sup>, Benedict's solution, or Fehling's solution. It is recommended that glucose tests based on enzymatic glucose oxidase reactions (such as Clinistix<sup>\*</sup>) be used.

A false-positive direct Coombs test has been reported during treatment with cephalosporin antibiotics; therefore, it should be recognized that a positive Coombs test may be due to the drug.

---

<sup>\*</sup> Reg. Trademark of Bayer Healthcare LLC subsidiary of Bayer Corporation.

**Usage in Pregnancy:**

The safety of cefixime tablets in the treatment of infection in pregnant women has not been established.

Reproduction studies have been performed in mice and rats at doses up to 400 times the human dose and have revealed no evidence of impaired fertility or harm to the fetus due to cefixime. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if the likely benefits of using AURO-CEFIXIME tablets outweigh the potential risk to the fetus and/or the mother.

**Labour and Delivery:**

Cefixime tablets has not been studied for use during labour and delivery.

**Nursing Mothers:**

It is not known whether cefixime is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when AURO-CEFIXIME tablets is administered to a nursing woman.

**Usage in Children (> 12 years of age):**

The use of AURO-CEFIXIME in children less than 12 years of age is not recommended.

**ADVERSE REACTIONS****Clinical Trials:**

Five percent (5%) of patients in the clinical trials discontinued therapy because of drug-related adverse reactions. Thirty-six percent of the pediatric patient population experienced at least one adverse reaction (mild 25%, moderate 9%, severe 2%). Forty-seven percent of the adult patients experienced at least one adverse reaction (mild 24%, moderate 19%, severe 4%). The most commonly seen adverse reactions in the clinical trials of the tablet formulation were gastrointestinal events, which were reported in 37% of all adult patients treated (mild 21%, moderate 13%, severe 3%). The predominant adverse events seen in adults in clinical trials with cefixime tablets (cefixime) were diarrhea 15%, (mild 7.2%, moderate 6.2%, severe 1.5%), headache 11%, stool changes 12%, nausea 9%, abdominal pain 5%, dyspepsia 3%, flatulence (3%), dizziness (3%) and vomiting (2%). The rates of the most prevalent adverse reactions were similar in the once a day and twice a day dosing regimens with the exception of headache, which appears slightly more frequently in adults, dosed once a day (12.9%) versus twice a day (8%).

These symptoms usually responded to symptomatic therapy or ceased when cefixime tablets was discontinued.

Several patients developed severe diarrhea and/or documented pseudomembranous colitis, and a

few required hospitalization.

When cefixime tablets was used as single 400 mg dose therapy in clinical trials in the treatment of uncomplicated gonorrhoea, adverse reactions which were considered to be related to cefixime tablets therapy, were reported for 5.9% (21/358) of patients. Clinically mild gastrointestinal side effects occurred in 3.7% of all patients, moderate events occurred in 0.9% of all patients and no adverse reactions were reported as severe. Individual event rates included diarrhea 1% and loose or frequent stools 1%. Incidence rates for all other adverse reactions reported for adults in these trials were less than 1%.

**Clinical Trial and Post-Market Adverse Drug Reactions:**

The following adverse reactions have been observed during clinical trial studies and/or during marketed use.

Blood and lymphatic system disorders:

Thrombocytopenia, thrombocytosis, leucopenia, eosinophilia, neutropenia, agranulocytosis, immune hemolytic anemia (see WARNINGS, Hemolytic Anemia).

Gastrointestinal disorders:

Diarrhea, stool changes, nausea, abdominal pain, dyspepsia, flatulence, vomiting.

General disorders and administration site conditions:

Drug fever, face oedema.

Hepatobiliary disorders: Jaundice (cholestatic and/or hepatocellular).

Immune system disorders:

Serum sickness-like reaction, anaphylactic reactions (urticaria and angioedema).

Infections and infestations:

Vaginitis, candidiasis, pseudomembranous colitis.

Investigations:

Elevations of alanine aminotransferase (ALT or SGPT), aspartate aminotransferase (AST or SGOT), alkaline phosphatase and bilirubin.

Elevations in Blood Urea Nitrogen (BUN) or creatinine.

Prolongation in prothrombin time.

Nervous system disorders:

Headaches, dizziness.

Renal and urinary disorders:

Acute renal failure including tubulointerstitial nephritis.

Reproductive system and breast disorders:

Genital pruritus.

Respiratory, thoracic and mediastinal disorders:

Dyspnea, respiratory distress.

Skin and subcutaneous tissue disorders:

Skin rashes, pruritus, urticaria, toxic epidermal necrolysis (TEN), drug rash with eosinophilia and systemic symptoms (DRESS), bullous skin reactions (erythema multiforme and Stevens-Johnson syndrome).

In addition to the adverse reactions listed above which have been observed in patients treated with cefixime tablets the following adverse reactions and altered laboratory tests have been reported for cephalosporin-class antibiotics: superinfection, renal dysfunction, toxic nephropathy, hepatic dysfunction including cholestasis, aplastic anemia, hemorrhage, elevated lactate dehydrogenase (LDH) and pancytopenia.

Several cephalosporins have been implicated in triggering seizures, particularly in patients with renal impairment when the dosage was not reduced. If seizures associated with AURO-CEFIXIME tablets occur, the drug should be discontinued. Anticonvulsant therapy can be given if clinically indicated (see DOSAGE AND ADMINISTRATION and OVERDOSAGE).

## **SYMPTOMS AND TREATMENT OF OVERDOSAGE**

For management of a suspected drug overdose, contact your regional Poison Control Centre immediately.
---

No specific antidote exists. General supportive measures are recommended.

Cefixime is not removed in significant quantities from the circulation by hemodialysis or peritoneal dialysis.

## **DOSAGE AND ADMINISTRATION**

**Adults:**

The recommended dose of AURO-CEFIXIME tablets (cefixime) is 400 mg once daily. When necessary, a dose of 200 mg (one-half of a 400 mg tablet) given twice daily may be considered except for urinary tract infections where once daily dosing must be used.

For treatment of uncomplicated gonococcal infections, a single oral dose of 400 mg is recommended.

Children weighing more than 50 kg or older than 12 years should be treated with the recommended adult dose.



**Duration of Therapy:**

Duration of dosage in clinical trials was 10 to 14 days. The duration of treatment should be guided by the patient's clinical and bacteriological response.

In the treatment of infections due to *Streptococcus pyogenes*, a therapeutic dose of AURO-CEFIXIME tablets should be administered for at least 10 days.

**Renal Impairment:**

AURO-CEFIXIME tablets may be administered in the presence of impaired renal function. Normal dose and schedule may be employed in patients with creatinine clearances of 40 mL/min or greater. Patients whose clearance is between 20 and 40 mL/min should be given 75% of the standard daily dosage. Patients whose creatinine clearance is less than 20 mL/min should be given 50% of the standard daily dosage.

Experience in children with renal impairment is very limited.

NOTE: Neither hemodialysis, nor peritoneal dialysis remove significant amounts of cefixime from the body.

## PHARMACEUTICAL INFORMATION


### Chemistry:

Trade Name: AURO-CEFIXIME

Proper Name: Cefixime

Chemical Name: (6R,7R)-7-[[[(Z)-2-(2-aminothiazol-4-yl)-2-[(carboxymethoxy)imino]acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid trihydrate.

### Structural Formula:



Molecular Formula: C<sub>16</sub>H<sub>15</sub>N<sub>5</sub>O<sub>7</sub>S<sub>2</sub>·3H<sub>2</sub>O

Molecular Weight: 507.5 g/mol

Description: A white or almost white powder. Slightly soluble in water, soluble in methanol, sparingly soluble in ethanol, practically insoluble in ethyl acetate.

<b>Dosage form</b>	<b>Tablets</b>
<b>Strength</b>	<b>400 mg</b>
<b>Description</b>	White to off-white, film-coated, capsule shaped, beveled edged tablets debossed with 'E' and breakline on one side and '8' and '7' separated by breakline on the other side.
<b>Composition</b>	<b>Non-medicinal Ingredients:</b> <i>Core tablet contains:</i> Calcium Hydrogen Phosphate Anhydrous (Calipharm A), Starch Pregelatinised (Starch 1500), Hydroxypropyl Cellulose (Klucel LF), Cellulose microcrystalline (Avicel PH-112) and Magnesium Stearate <i>Coating contains:</i> Polyvinyl alcohol, Titanium Dioxide, Talc, Lecithin (Soya) and Xanthan gum.
<b>Packaging</b>	Blister Pack of 1x7's, 1x10's & 2x5's count. HDPE Pack of 20's & 500's count.

### Storage:

Store at room temperature (15°C to 30°C). Protect from moisture.

## Comparative Bioavailability Studies

A double blind, randomized, two-treatment, two-sequence, two-period, crossover, single-dose comparative oral bioavailability study of AURO-CEFEXIME Tablets 400 mg (Test) of Aurobindo Pharma Limited, India manufactured for Auro Pharma Inc. (Canada) and Suprax<sup>®</sup> (Cefixime) Tablets 400 mg (Reference) of Sanofi-Aventis Canada Inc., Canada was conducted in 24 healthy, adult, male subjects under fasting conditions.

**Summary Table of the Comparative Bio-availability Data**

<b>Cefixime (1 x 400 mg) From measured data Geometric Mean Arithmetic Mean (CV %)</b>				
<b>Parameter</b>	<b>Test*</b>	<b>Reference<sup>†</sup></b>	<b>% Ratio of Geometric Means</b>	<b>90% Confidence Interval</b>
<b>AUC<sub>0→t</sub> (hr.µg/mL)</b>	41.4 42.8 (25.2)	40.7 42.5 (29.4)	101.7	92.7 – 111.6
<b>AUC<sub>0→∞</sub> (hr.µg/mL)</b>	42.7 44.2 (25.4)	42.2 44.0 (30.1)	101.3	92.5 – 111.0
<b>C<sub>max</sub> (µg/mL)</b>	4.9 5.1 (24.2)	4.7 4.9 (27.7)	104.5	95.9 – 113.8
<b>T<sub>max</sub><sup>§</sup> (h)</b>	4.3 (2.5-6.0)	4.5 (4.0-8.0)		
<b>T<sub>1/2</sub><sup>§</sup> (h)</b>	4.0 (18.5)	4.1 (18.0)		

\*AURO-CEFEXIME (Cefixime Tablets 400 mg), by Auro Pharma Inc.

<sup>†</sup> SUPRAX (Cefixime Tablets 400 mg), of Sanofi-Aventis Canada Inc., Canada were purchased from Canada.

<sup>§</sup> Expressed as the median (range) only.

<sup>§</sup> Expressed as arithmetic mean (%CV) only.

## MICROBIOLOGY

*In vitro* activity of cefixime against various gram-positive and gram-negative organisms is presented in Table 2.

**Table 2 - Activity of cefixime against clinical isolates of bacteria**

<b>Organism</b>	<b>Number of isolates</b>	<b>MIC<sub>50</sub><sup>a</sup> (µg/mL)</b>	<b>MIC<sub>90</sub> (µg/mL)</b>
<b>GRAM-NEGATIVE</b>			
<i>Acinetobacter calcoaceticus</i>	434	9.07	19.41
<i>Moraxella catarrhalis</i> (formerly <i>Branhamella catarrhalis</i> )	108	0.14	0.40
<i>Campylobacter jejuni</i>	10	1.60	1.60
<i>Citrobacter amalonaticus</i>	56	0.32	1.54
<i>Citrobacter diversus</i>	154	0.12	0.16
<i>Citrobacter Freundii</i>	766	2.01	57.40
<i>Enterobacter aerogenes</i>	644	0.85	38.30
<i>Enterobacter agglomerans</i>	63	0.40	25.70
<i>Enterobacter cloacae</i>	1532	2.48	48.40
<i>Enterobacter species</i>	442	3.27	20.00
<i>Escherichia coli</i>	6190	0.19	0.71
<i>Haemophilus influenzae</i>	751	0.04	0.13
<i>H. influenzae</i> , Ampicillin-susceptible	2236	0.03	0.12
<i>H. influenzae</i> , Ampicillin-resistant	30	0.08	0.08
<i>H. influenzae</i> , Beta-lactamase-negative	82	0.05	0.05
<i>H. influenzae</i> , Beta-lactamase-positive	188	0.03	0.06
<i>H. parainfluenzae</i>	2	0.05	0.05
<i>Klebsiella oxytoca</i>	490	0.04	0.06
<i>Klebsiella pneumoniae</i>	2760	0.06	0.10
<i>Klebsiella species</i>	128	0.08	0.34
<i>Morganella morganii</i>	741	0.74	17.00
<i>Neisseria gonorrhoeae</i>	325	0.15	0.15
<i>Neisseria gonorrhoeae</i> Beta-lactamase-negative	325	0.008	0.015
<i>Neisseria gonorrhoeae</i> Beta-lactamase-positive	195	0.008	0.03
<i>Neisseria gonorrhoeae</i> Tetracycline-resistant	99	0.008	0.015
<b>GRAM-NEGATIVE</b>			
<i>Neisseria gonorrhoeae</i> Chromasomally-resistant	173	0.015	0.06
<i>Neisseria meningitidis</i>	19	0.06	0.06

<b>Organism</b>	<b>Number of isolates</b>	<b>MIC<sub>50</sub><sup>a</sup> (µg/mL)</b>	<b>MIC<sub>90</sub> (µg /mL)</b>
<i>Pasteurella multocida</i>	1	0.06	0.06
<i>Proteus mirabilis</i>	1983	0.05	0.06
<i>Proteus vulgaris</i>	658	0.03	0.10
<i>Proteus</i> , indole-positive	118	0.06	5.91
<i>Proteus</i> species	4	0.25	0.25
<i>Providencia rettgeri</i>	346	0.05	0.37
<i>Providencia stuartii</i>	241	0.10	0.67
<i>Providencia</i> species	15	0.40	2.15
<i>Pseudomonas aeruginosa</i>	2003	47.00	53.10
<i>Pseudomonas cepacia</i>	132	2.42	6.87
<i>Salmonella enteritidis</i>	27	0.17	0.34
<i>Salmonella</i> species	337	0.09	0.21
<i>Serratia marcescens</i>	1552	0.71	12.90
<i>Shigella</i> species	327	0.12	0.48
<i>Yersinia enterocolitica</i>	62	0.37	1.62
<b>GRAM-POSITIVE</b>			
<i>Enterococcus faecalis</i>	161	65.60	100.00
<i>Enterococcus</i> species	988	33.00	33.00
<i>Staphylococcus aureus</i>	1949	17.50	36.50
<i>Staphylococcus epidermidis</i>	438	10.80	61.80
<i>Streptococcus agalactiae</i>	48	0.21	0.32
<i>Streptococcus pyogenes</i>	830	0.11	0.16
<i>Streptococcus</i> Group B	112	0.17	0.22
<i>Streptococcus pneumoniae</i>	547	0.13	0.29
<i>Streptococcus viridans</i>	42	0.84	26.70

<sup>a</sup> Geometric mean MIC for 50% and 90% of the isolates.  
Abbreviation: MIC, minimal inhibitory concentration.

The following organisms are resistant to cefixime:

- *Pseudomonas* species
- strains of group D streptococci (including enterococci)
- *Listeria monocytogenes*
- most strains of staphylococci (including methicillin-resistant strains)
- most strains of *Enterobacter*
- most strains of *Bacteroides fragilis* and *Clostridia*.

## Susceptibility testing:

### Susceptibility Tests: Diffusion Techniques:

Quantitative methods that require measurement of zone diameters give an estimate of antibiotic susceptibility. One such procedure has been recommended for use with disks to test susceptibility to cefixime. Interpretation involves correlation of the diameters obtained in the disk test with the minimum inhibitory concentration (MIC) for cefixime.

Reports from the laboratory giving results of the standard single-disk susceptibility test with a 5 µg cefixime disk should be interpreted according to the following criteria:

**Table 3 - Recommended Susceptibility Ranges: Agar Disk Diffusion**

Organisms	Resistant	Moderately Resistant	Susceptible
<i>Neisseria gonorrhoeae</i>	-	-	≥ 31 mm
All other organisms	≤ 15 mm	16-18 mm	≥ 19 mm

<sup>a</sup> Using GC Agar Base with a defined 1% supplement with cysteine.

A report of "Susceptible" indicates that the pathogen is likely to be inhibited by generally achievable blood levels. A report of "Moderately Susceptible" indicates that inhibitory concentrations of the antibiotic may well be achieved if high dosage is used or if the infection is confined to tissues and fluids (e.g., urine) in which high antibiotic levels are attained. A report of "Resistant" indicates that achievable concentrations of the antibiotic are unlikely to be inhibitory and other therapy should be selected.

Standardized procedures require the use of laboratory control organisms. The 5 µg disk should give the following zone diameter:

**Table 4 - Control organisms: Agar Disk Diffusion**

Organism	Zone Diameter (mm)
<i>E. coli</i> ATCC 25922	23-27
<i>N. gonorrhoeae</i> ATCC 49226a	37-45

<sup>a</sup> Using GC Agar Base with a defined 1% supplement with cysteine.

The class disk for cephalosporin susceptibility testing (the cephalothin disk) is not appropriate because of spectrum differences with cefixime. The 5 µg cefixime disk should be used for all *in vitro* testing of isolates.

### Dilution Techniques:

Broth or agar dilution methods can be used to determine the minimum inhibitory concentration (MIC) value for susceptibility of bacterial isolates to cefixime. The recommended susceptibility breakpoints are as follows:

**Table 5 - MIC Interpretive Standards ( $\mu\text{g}/\text{mL}$ )**

Organisms	Resistant	Moderately Resistant	Susceptible
<i>Neisseria gonorrhoeae</i> <sup>a</sup>	-	-	$\leq 0.25$
All other organisms	$\geq 4$	2	$\leq 1$

As with standard diffusion methods, dilution procedures require the use of laboratory control organisms. Standard cefixime powder should give the following MIC ranges in daily testing of quality control organisms:

**Table 6 - Control organisms: Dilution technique**

Organism	MIC Range ( $\mu\text{g}/\text{mL}$ )
<i>E. coli</i> ATCC 25922	0.25 - 1
<i>S. aureus</i> ATCC 29213	8 - 32
<i>N. gonorrhoeae</i> ATCC 49226 <sup>a</sup>	0.004 - 0.03

<sup>a</sup> Using GC Agar Base with a defined 1% supplement with cysteine.

## PHARMACOLOGY

### Animal Pharmacology:

#### Tissue Distribution/Accumulation:

In rats, <sup>14</sup>C-labelled cefixime was distributed (in order of descending amounts) to the kidneys, lungs, liver, heart, spleen, and brain at 1 hour following a single oral dose of cefixime and to the kidneys, urinary bladder, blood, liver, and lungs at 5 minutes after a single intravenous dose. In dogs, tissue radioactivity was noted in bile, kidney, liver, lung, testes, heart, and brain after single or multiple intravenous dosing with <sup>14</sup>C-labelled cefixime

After multiple oral dosing, accumulation of cefixime was negligible in the serum and urine of adult rats and dogs. The doses used in these studies were 100 and 1000 mg/kg/day administered for 1 month to rats and up to 400 mg/kg/day (100, 200 and 400 mg/kg/day) for 53 weeks to dogs. In addition, there was no evidence of drug accumulation in serum or urine after two weeks of intravenous dosing (320 and 1000 mg/kg/day) in adult dogs.

In animal studies, it was noted that cefixime is excreted in the bile in excess of 10% of the administered dose.

### Human Pharmacokinetics:

#### Absorption:

Cefixime, given orally, is about 40% to 50% absorbed.

In adults a single 200 mg tablet of cefixime produces an average peak serum concentration of approximately 2  $\mu\text{g}/\text{mL}$  (range 1 to 4  $\mu\text{g}/\text{mL}$ ); a single 400 mg tablet produces an average

concentration of approximately 3.5 µg/mL (range 1.3 to 7.7 µg/mL).

Peak serum concentrations occur between 2 and 6 hours following oral administration of a single 200 mg tablet or a single 400 mg tablet of cefixime. See Table 7.

**Table 7 - Serum Levels of Cefixime in Adults after Administration of Tablets (µg/mL)**

DOSE	1hr	2hr	4hr	6hr	8hr	12hr	24hr
100 mg*	0.3	0.8	1.0	0.7	0.4	0.2	0.2
200 mg	0.7	1.4	2.0	1.5	1.0	0.4	0.03
400 mg	1.2	2.5	3.5	2.7	1.7	0.6	0.04

\* ½ x 200 mg tablets

The serum half-life of cefixime in healthy subjects is independent of dosage form and averaged 3 to 4 hours but may range up to 9 hours in some normal volunteers.

Metabolism:

There is no evidence of metabolism of cefixime *in vivo*.

Excretion:

Cefixime is excreted by renal and biliary mechanisms.

The urinary recoveries of orally administered 200 mg and 400 mg doses of cefixime in 12 healthy men are presented in Table 9. Over a 24 hour period, approximately 20% and 16% of a 200 mg and 400 mg dose of cefixime, respectively was excreted in the urine. An additional 10% or more was recovered from bile.

**Table 8 - Mean urinary excretion of cefixime after 200 and 400 mg dose in 12 healthy men**

DOSE	24-h Urinary Recovery of Cefixime (% of administered dose)	Maximum Concentration of Cefixime in Urine (µg/mL)
200 mg	20.0	107
400 mg	16.1	164

Distribution and Accumulation:

Cefixime appears to be widely distributed, however, adequate tissue concentration data relating to tablet is not available.

Serum protein binding is concentration independent with a bound fraction of approximately 65%. Multiple dose studies conducted with 200 mg or 400 mg tablets in normal volunteers showed there was little or no accumulation of drug in serum or urine after dosing for 14 days.

Adequate data on cerebrospinal fluid (CSF) levels of cefixime are not available.



## Factors Affecting Pharmacokinetics:

### RENAL

In patients with moderate impairment of renal function (20 to 40 mL/min creatinine clearance), the average serum half-life of cefixime is prolonged to 6.4 hours. In severe renal impairment (5 to 20 mL/min creatinine clearance), the half-life increased to an average of 11.5 hours. The drug is not cleared significantly from the blood by hemodialysis or peritoneal dialysis.

### AGE (ELDERLY PATIENTS)

All adults may be given the same dosage regimen of AURO-CEFIXIME regardless of age. A comparative pharmacokinetic study in 12 healthy men over 64 years of age and in 12 men 18 to 35 years of age used a 400 mg dose of cefixime administered once daily for 5 days. Blood and urine samples were obtained at frequent intervals. Table 9 shows the mean serum concentration-time profiles of cefixime.  $C_{max}$  and AUC were greater in the elderly on the first (4.77  $\mu\text{g/mL}$  and 41.0  $\mu\text{g.h/mL}$ ) and fifth (5.45  $\mu\text{g/mL}$  and 49.5  $\mu\text{g.h/mL}$ ) days of dosing when compared with corresponding values in the young subjects on day 1 (3.64  $\mu\text{g/mL}$  and 28.6  $\mu\text{g.h/mL}$ ) and day 5 (4.53  $\mu\text{g/mL}$  and 34.9  $\mu\text{g.h/mL}$ ). These differences were statistically significant, but their magnitude was too small to be of clinical significance.  $T_{1/2}$  values were not different between the two groups.

**Table 9 - Mean pharmacokinetic parameters for cefixime on day 5 in young and elderly subjects given 400 mg daily for 5 days**

GROUP	AGE (yrs)	$C_{max}$ ( $\mu\text{g/mL}$ )	$T_{max}$ (h)	AUC <sub>0-inf.</sub> ( $\mu\text{g.h/mL}$ )	$T_{1/2}$ (h)	fe (% dose)
Young	20-32	4.74	3.9	34.9	3.5	20.2
Elderly	65-74	5.68	4.3	49.5	4.2	24.6

Abbreviations:  $C_{max}$  = peak serum concentration;  
 $T_{max}$  = time to reach maximum serum concentration;  
AUC = area under the serum concentration versus time curve;  
 $T_{1/2}$  = serum half-life;  
fe = urinary recovery of cefixime expressed as a fraction of the administered dose.

### FOOD (EFFECT OF FOOD ON ABSORPTION)

There was no clinically significant effect of food on the absorption of cefixime. Cefixime tablets were administered as a single 400 mg dose with and without food in a crossover study in 20 healthy men.  $C_{max}$  values were 4.22 and 4.24  $\mu\text{g/mL}$  in the fed and fasted states, respectively. Food slowed the time to reach  $C_{max}$  by about 1 hour (3.8 hours versus 4.8 hours). This effect is of no clinical significance and probably reflects a small delay in gastric emptying due to the presence of food. Urinary recovery was unaffected by the presence of food: 18.4% (fed) and 17.7% (fasted) of the doses were recovered in 24 hours.

## DRUG INTERACTION

A four-way crossover study in 12 healthy men evaluated the pharmacokinetics of cefixime when administered with, before, and after aluminum/magnesium containing antacids. The administration of antacid did not significantly alter the pharmacokinetic parameters of cefixime.

In a protein-binding interaction study using human serum, there was no statistically significant change in the fraction of unbound cefixime with the addition of acetaminophen, heparin, phenytoin, ibuprofen, furosemide or diazepam at their reported maximum therapeutic concentrations. With salicylic acid there was a significant, approximately two fold increase from 35% to 66% in the unbound fraction. When the interaction was studied in dogs, it was confirmed that ASA-related products (i.e. salicylic acid) caused an increase in the unbound fraction of cefixime, which ultimately resulted in an increase in the volume of distribution and the clearance of the drug. However, since the volume of distribution and clearance increased to the same extent, there was no net effect on the elimination half-life of cefixime.

An open-label, randomized, crossover study in 15 healthy men found that concomitant administration of ASA (650 mg) with cefixime 400 mg tablet had no effect on protein binding, half-life, or renal clearance of cefixime. ASA did, however, appear to decrease absorption of cefixime as evidenced by a 26% reduction in C<sub>max</sub> and 19% reduction in AUC values.

## TOXICOLOGY

### Single-Dose Toxicity:

Oral LD<sub>50</sub> values were > 10 g/kg for mice (5-10/sex/group), rats (5-10/sex/group) and rabbits (5/sex/group). In 13 dogs, lethal dose determination was limited by emesis occurring at a single oral dose of 0.32 g/kg or higher; there was no mortality among these dogs. After intravenous, intraperitoneal, or subcutaneous injection, LD<sub>50</sub> values were greater than 3, 7, or 10 g/kg, respectively, for mice (5-10/sex/group), and 5, 8 or 10 g/kg, respectively for rats (5-10/sex/group). The tolerated intravenous dose in rabbits (3M/group) was 0.32 g/kg. In one male dog, a total intravenous infusion dose of 5.5 g/kg was not associated with lethality. Signs of toxicity in this dog were decreased blood pressure and respiratory rate, emesis, and electrocardiogram abnormalities.

Following oral dosing in young animals (10/sex/group), LD<sub>50</sub> values were 3 g/kg in 4-day old mice, 7 g/kg in 4-day old rats, and > 10 g/kg in 20- and 34-day old rats. Oral doses of 3.2 g/kg in 2 week old dogs (2M/1F) and 8-week old dogs (1M/2F) were not lethal, did not affect body weight and were not associated with gross postmortem or histopathologic changes. Young dogs were able to tolerate higher doses of cefixime without emesis than were older dogs due to the incomplete maturation of the emetic centre in young dogs.

### Multiple-Dose Toxicity:

Multiple-dose oral toxicity studies were conducted for periods of 4 weeks to 1 year in rats and dogs. Studies in rats utilized doses up to 3200 mg/kg administered once daily (15-20/sex/group) or up to 500 mg/kg given twice daily (12/sex/group). Studies in dogs (4-5/sex/group) employed doses up to 200 mg/kg administered twice daily. In addition, studies of 2 weeks duration were conducted in rats (10/sex/group) and dogs (2/sex/group) to assess the effects of daily intravenous

administration of cefixime. An 8-day study in dogs (3/sex/group) utilizing ascending intravenous doses of 80 to 2500 mg/kg was conducted to assess the nephrotoxic potential of cefixime. The results of these studies follow.

Soft feces, enlargement of the cecum and increased cecal weights were seen across all rat studies. These are common findings in rats following treatment with antibiotics. Decreased urobilinogen was also observed and is considered to be related to changes in the intestinal flora resulting in reduced production of urobilinogen from bilirubin. The chronic nephropathy of aging rats was exacerbated following administration of high doses of cefixime (1000 mg/kg/day) for 53 weeks. In dog studies, emesis, which was related to treatment, was noted in some animals receiving cefixime orally; there were no other findings related to cefixime following oral administration. In an 8-day, ascending intravenous dose study in dogs, cefixime was not lethal at a cumulative dose of 7295 mg/kg. In this study, emesis and nephrotoxicity (i.e. elevated blood urea nitrogen and serum creatinine; protein, glucose, and ketones in the urine; tubular degeneration and necrosis of kidneys) were seen.

The multiple-dose oral toxicity of cefixime was also investigated in young rats (15/sex/group) and dogs (3/sex/group) at doses up to 3200 mg/kg and 400 mg/kg, respectively, administered once daily for 5 weeks. In addition, the oral toxicity of cefixime was investigated in young dogs (7/sex/group) at single daily doses of up to 180 mg/kg or 60 mg/kg administered twice daily for 5 weeks. The rat study showed cecal effects similar to those seen in the studies with adult animals. Soft feces were noted in all dose groups. Results of the dog studies showed no drug-related toxicity at doses up to 400 mg/kg/day in adult animals and up to 180 mg/kg/day in young animals.

#### **Mutagenicity:**

Cefixime did not exhibit mutagenic or clastogenic potential in a battery of genetic toxicology tests. Drug concentrations of 0.001 to 1.0 µg/plate were used in microbial mutagenicity tests, 3200 µg/mL in a mammalian point mutation assay, 1 to 2500 µg/mL in an unscheduled DNA synthesis test, and 6000 to 10 000 µg/mL in an *in vitro* cytogenetics test. Two investigational product (IP) doses of 100 to 3200 mg/kg were given to mice in an *in vivo* micronucleus test.

#### **Reproductive Toxicity:**

Fertility and general reproductive performance, teratology, and perinatal/postnatal studies were conducted in animals. In the fertility and reproductive performance study in rats, no difference between control and drug-treated animals was detected in mating behavior, pregnancy rate, litter parameters (determined at sacrifice on day 13 of pregnancy), length of pregnancy or delivery at oral doses up to 1000 mg/kg/day administered to males (for 68 days prior to pairing and during the cohabitation period) and females (for 14 days before pairing to weaning). The results of teratology studies in mice and rats show that cefixime, at doses up to 3200 mg/kg/day is not teratogenic. In these studies in mice and rats, cefixime did not affect postnatal development or reproductive capacity of the F<sub>1</sub> generation or fetal development of the F<sub>2</sub> generation. In studies designed to assess the teratogenic potential of cefixime in rabbits, cefixime at doses of 3.2, 10 or 32 mg/kg given daily on days 6 through 18 of pregnancy was not teratogenic in this species. Toxic responses (abortions and/or maternal deaths) typically associated with the administration of antibiotics in this species were elicited at ≥ 10 mg/kg. The results of studies in rats designed to

assess the effect of cefixime administered to dams during the perinatal and postnatal periods, at oral doses up to 3200 mg/kg/day, show that cefixime does not affect the duration of pregnancy, process of parturition, or development and viability of offspring. In addition, reproductive capacity of the F<sub>1</sub> generation and development of their fetuses (F<sub>2</sub>) were not affected.

**Antigenicity:**

Results of tests in mice, rats, rabbits, and guinea pigs show that cefixime alone has no antigenic potential when administered orally and only weak antigenic potential when administered parenterally with adjuvants or carrier proteins. There was no cross-reactivity detected between cefixime and several other cephalosporin antibiotics.

**Carcinogenesis:**

Lifetime studies in animals to evaluate carcinogenic potential have not been conducted.

## BIBLIOGRAPHY

1. Asmar, B., Barone, J., Clark, P., Simpkins, D. A comparative trial of cefixime and amoxicillin in the treatment of acute otitis media with effusion. Workshop, 15th International Congress of Chemotherapy, July 1987. *Advances in Experimental and Clinical Chemotherapy* 1988; 1: 44-48.
2. Barry, A.L., Jones, R.N. Cefixime: spectrum of antibacterial activity against 16,016 clinical isolates. *Pediatric Infectious Disease* 1987; 6: 954-957.
3. Beumer, H.M. Cefixime versus amoxicillin/clavulanic acid in lower respiratory tract infections. *International Journal of Clinical Pharmacology* 1989; 27: 30-33.
4. Bergeron, M.G., Lavoie, G.Y., Boucher, F.D.W. Comparative bactericidal activity of cefixime, carumonon, enoxacin and roxithromycin with those of other antibiotics against resistant *Haemophilus influenzae* including beta-lactam tolerant strains. *Journal of Antimicrobial Chemotherapy* 1987; 20: 663-669.
5. Bialer, M., Tonelli, A.P., Kantrowitz, J.D., Yacobi, A. Serum protein binding of a new oral cephalosporin, CL 284,635, in various species. *Drug Metabolism and Disposition* 1986; 14: 132-136.
6. Bialer, M., Wu, W.H., Faulkner, R.D., Silbert, B.M., Yacobi, A. *In vitro* protein binding interaction studies involving cefixime. *Biopharmaceutics and Drug Disposition* 1988; 9: 315-320.
7. Bowie, W.R., Shaw, C.E., Chan, D.G.W., Boyd, J., Black, W.A. *In vitro* activity of difloxacin hydrochloride (A56619), A56620 and cefixime (CL 284,635; FK027) against selected genital pathogens. *Antimicrobial Agents and Chemotherapy* 1986; 30: 590-593.
8. Brittain, D.C., Scully, B.E., Hirose, T., Neu, H.C. The pharmacokinetic and bactericidal characteristics of oral cefixime. *Clinical Pharmacology and Therapeutics* 1985; 38: 590-594.
9. Carenfelt, C. Melen, I., Odkvist, L., Olsson, O., Prellner, K., Rudblad, S., Savolainen, S., Skaftason, S., Sorri, M., Synnerstad, B. Treatment of Sinus Empyema in Adults. *Acta Otolaryngol (StockH)* 1990; 110: 128-135.
10. Centers of Disease Control. Plasmid-mediated antimicrobial resistance in *N. gonorrhoeae* - United States; 1988 and 1989. MMWR 1990; 39:284-293.
11. Counts, G.W., Baugher, L.K., Ulness, B.K., Hamilton, D.J. Comparative in vitro activity of the new oral cephalosporin cefixime. *European Journal of Clinical Microbiology and Infectious Disease* 1988; 7: 428-431.
12. Cullman, W., Dick, W., Opferkuch, W. Antibacterial activity of cefixime with regard to

plasmid and chromosomally mediated beta-lactamases. Workshop, 15th International Congress of Chemotherapy, July 1987. *Advances in Experimental and Clinical Chemotherapy* 1985; 1: 9-14.

13. Dornbusch, K. Kronvall, G., Goransson, E. Comparative *in vitro* antibacterial activity and beta-lactamase stability of cefixime. Workshop, 15th International Congress of Chemotherapy, July 1987. *Advances in Experimental and Clinical Chemotherapy* 1988; 1: 1-8.
14. Dorow, P. Safety and efficacy of cefixime in comparison to cefaclor in respiratory tract infections. Workshop, 15th International Congress of Chemotherapy, July 1987. *Advances in Experimental and Clinical Chemotherapy* 1988; 1: 33-37.
15. Easmon, C.S.F., Ison, C.A. *Neisseria gonorrhoeae*: a versatile pathogen. *J. Clin Pathol* 1987; 40:1088-1097.
16. Faulkner, R.D., Bohaychuk, W., Desjardins, R.E., Look, Z.M., Haynes, J.D., Weiss, A.I., Silber, B.M. Pharmacokinetics of cefixime after once-a-day and twice-a-day dosing to steady state. *Journal of Clinical Pharmacology* 1987; 27: 807-812.
17. Faulkner, R.D., Bohaychuk, W., Haynes, J.D., Desjardins, R.E., Yacobi, A., Silber, B.M. Pharmacokinetics of cefixime in the fasted and fed state. *European Journal of Clinical Pharmacology* 1988; 34: 525-528.
18. Faulkner, R.D., Bohaychuk, W., Lane, R.A., Haynes, J.D., Desjardins, R.E., Yacobi, A., Silber, B.M. Pharmacokinetics of cefixime in the young and elderly. *Journal of Antimicrobial Chemotherapy* 1988; 21: 787-794.
19. Faulkner, R.D., Fernandez, P., Lawrence, G., Sia, L.L., Falkowski, A.J., Weiss, A.I., Yacobi, A., Silber, B.M. Absolute bioavailability of cefixime in man. *The Journal of Clinical Pharmacology* 1988; 28: 700-706.
20. Faulkner, R.D., Yacobi, L.A., Barone J.S., Kaplan S.A., Silber, B.M. Pharmacokinetic profile of cefixime in man. *Pediatric Infectious Disease* 1987; 6: 963-970.
21. Finegold, S.M., Ingram-Drake, L., Gee, R., Reinhardt, J., Edelstein, M.A.C., MacDonald, K., Wexler, H. Bowel flora changes in humans receiving cefixime (CL 284,635) or cefaclor. *Antimicrobial Agents and Chemotherapy* 1987; 31: 443-446.
22. Fuchs, P.C., Jones, R.N., Barry, A.L., Thornsberry, C., Ayers, L.W., Gavan, L., Gerlach, E.H. In vitro evaluation of cefixime (FK 027, FR 17027, CL 284,635): Spectrum against recent clinical isolates, comparative antimicrobial activity, beta-lactamase stability and preliminary susceptibility testing criteria. *Diagnostic Microbiology and Infectious Diseases* 1986; 5: 151-162.
23. Greene, D., Anslow, J., Bohaychuk, W., Faulkner, R., Silber, M., Woodward, D,

- Dabrowski, J., Kibbe, A. Pharmacokinetics of cefixime in the fed and fasted state. Workshop, 15th International Congress of Chemotherapy, July, 1987. *Advances in Experimental and Clinical Chemotherapy* 1988; 1: 21-23.
24. Hegran, D.W., Lefebvre, K., Willetts, V., Bowie, W.R. Single-dose oral cefixime versus amoxicillin plus probenecid for the treatment of uncomplicated gonorrhea in men. *Antimicrob Agents Chemother* 1990; 34:355-357.
  25. Hook, E.W. III, Holmes, K.K., Hansfield, H.H. Division of Infectious Diseases, Department of Medicine, University of Washington, Harborview Medical Center, Seattle, Washington. Letter of January 7, 1985 addressed to Al Dornbush with data.
  26. Howie, V.M., Owen, M.J. Bacteriologic and clinical efficacy of cefixime compared with amoxicillin in acute otitis media. *Pediatric Infectious Disease* 1987; 6: 989-991.
  27. Iravani, A., Richard, G.A., Johnson, D., Bryant, A. A double-blind, multicenter comparative study of the safety and efficacy of cefixime versus amoxicillin in the treatment of acute urinary tract infections in adult patients. *American Journal of Medicine* 1988; 85 (Suppl. 3A): 27-25.
  28. Janda, Wm., Department of Medical Laboratory Sciences, The University of Illinois at Chicago, Chicago, Ill. Letter of September 23, 1988 addressed to Lynne Fredericks, with data.
  29. Jones, R.N., Department of Pathology, The University of Iowa Hospitals and Clinics, Iowa City, Iowa. Letter of October 4, 1990 addressed to Lynne Fredericks, with data.
  30. Kamidono, S., Arakawa, S., Kataoka, N., Hikosaka, K., Mita, T., Ishigami, J. *In vitro* and clinical evaluation of FK027 for the treatment of urinary tract infections. 14th International Congress of Chemotherapy, Kyoto, 23-28 June, 1985. Japan Convention Services, Inc., 1985.
  31. Kamimura, T., Kojo, H., Matsumoto, Y., Mine, Y., Goto S., Kuwahara, S. *In vitro* and *in vivo* antibacterial properties of FK027, a new orally active cephem antibiotic. *Antimicrobial Agents and Chemotherapy* 1984; 25: 98-104.
  32. Kawamura, S., Fujimaki, Y., Sugita, R., Watanabe, I., Nakamura, M., Asai, S. Tissue distributions and clinical results with cefixime for ENT infections. Workshop, 15th International Congress of Chemotherapy, July 1987. *Advances in Experimental Clinical Chemotherapy* 1988; 1: 24-32.
  33. Kenna, M., Bluestone, C.D., Fall, P., Stephenson, J., Kurs-Lasky, M., Wucher, F.P., Blatter, M.M., Reisinger, K.S. Cefixime vs cefactor in the treatment of acute otitis media in infants and children. *Pediatric Infectious Disease* 1987; 6: 992-996.
  34. Kiani, R., Johnson, D., Nelson, B. Clinical results of cefixime 200mg bid in the treatment

- of patients with acute respiratory tract infections. Workshop, 15th International Congress of Chemotherapy, July 1987. *Advances in Experimental and Clinical Chemotherapy* 1988; 1: 38-43.
35. Kiani, R., Johnson, D., Nelson B. Comparative multicentre studies of cefixime and amoxicillin in the treatment of respiratory tract infections. *American Journal of Medicine* 1988; 85: 6-13.
  36. Krepel, C.J., Schopf, L.R., Gordon, R.C., Edmiston, C.E. Comparative *in vitro* activity of cefixime with eight other antimicrobials against Enterobacteriaceae, streptococci and *Haemophilus influenzae*. *Current Therapeutic Research* 1988; 43: 296-302.
  37. Kuhlwein, A., Hies, B.A. Efficacy and safety of a single 400 mg oral dose of cefixime in the treatment of uncomplicated gonorrhoea. *Eur J Clin Microbiol Infect Dis* 1989; 8:261-262.
  38. Kumar, A., Kelly, K.J. In vitro activity of cefixime (CL 284635) and other antimicrobial agents against *Haemophilus* isolates from pediatric patients. *Chemotherapy* 1988, 34: 30-35,
  39. McLinn, S.E. Randomized, open label, multicenter trial of cefixime compared with amoxicillin for treatment of acute otitis media with effusion. *Pediatric Infectious Disease* 1987; 6: 997-1001.
  40. Nakashima, M., Uematsu, T., Takiguchi, Y., Kanamaru, M. Phase I study of cefixime, a new oral cephalosporin. *Journal of Clinical Pharmacology* 1987; 27: 425-431.
  41. Neu, H.C. In vitro activity of a new broad spectrum beta-lactamase-stable oral cephalosporin, cefixime. *Pediatric Infectious Disease* 1987; 6: 958-962.
  42. Neu, H.C., Chin, N.X., Labthavikul, P. Comparative *in vitro* activity and beta-lactamase stability of FR 17027, a new orally active cephalosporin. *Antimicrobial Agents and Chemotherapy* 1984; 26: 174-180.
  43. Powell, M., Kentsia-Carouzou, C., Voutsinas, D., Williams, J.D. A comparison of the *in vitro* activity of ampicillin and cefixime against 2458 clinical isolates of *Haemophilus influenzae*. Workshop, 15th International Congress of Chemotherapy, July, 1987. *Advances in Experimental and Clinical Chemotherapy* 1988; 1: 15-17.
  44. Risser, W.L., Barone, J.S., Clark, P.A., Simpkins, D.L. Noncomparative open label multicentre trial of cefixime for treatment of bacterial pharyngitis, cystitis, pneumonia in pediatric patients. *Pediatric Infectious Disease* 1987; 6: 1002-1006.
  45. Silber, D.M., Bohaychuk, W., Stout, M., Haynes, J.D., Schneider, J., Woodward, D.L., Look, Z.M., Weiss, A.I., Yacobi, A., Faulkner, R.D. Pharmacokinetics of cefixime in young and elderly volunteers. Workshop, 15th International Congress of Chemotherapy,



July 1987. *Advances in Experimental and Clinical Chemotherapy* 1988; 1: 18-20.

46. Smith, S.M., Eng, R.H.K. Activity of Cefixime (FK027) for resistant gram-negative bacilli. *Chemotherapy* 1988; 34: 455-461.
47. Stone, J.W., Liong, G., Andrews, J.M., Wise, R. Cefixime, *in vitro* activity, pharmacokinetics and tissue penetration. *Journal of Antimicrobial Chemotherapy* 1989; 23: 221-228.
48. Tally, F.P., Desjardins, R.E., McCarthy, E.F., Cartwright, K. Safety profile of cefixime. *Pediatric Infectious Disease* 1987; 6: 976-980.
49. Product Monograph SUPRAX (Cefixime tablets 400 mg) sanofi-aventis Canada Inc. Date of Revision: July 6, 2012.